PF 5231023

Drug Profile

PF 5231023

Alternative Names: PF-05231023; PF-5231023

Latest Information Update: 05 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antihyperglycaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 05 Mar 2014 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (IV)
  • 01 Dec 2013 Pfizer terminates a phase I trial for Type-2 diabetes mellitus in USA (NCT01923389)
  • 30 Sep 2013 Pfizer completes a phase I trial in Type-2 diabetes mellitus in USA (NCT01673178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top